LauraDichtelMD
Endocrinology • Boston, MADiabetes, Lipid Metabolism, Pituitary Disorders & Neuroendocrinology
Instructor In Medicine, Harvard Medical School and Assistant in Medicine, Massachusetts General Hospital
Dr. Dichtel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
# BUL457
Boston, MA 02114Phone+1 617-724-3614Fax+1 617-726-5072
Education & Training
Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2012 - 2015
Brigham and Women's HospitalResidency, Internal Medicine, 2009 - 2012
Yale School of MedicineClass of 2009
Certifications & Licensure
MA State Medical License 2012 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Clinical Trials
- The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease Start of enrollment: 2022 Aug 10
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 58 citationsClonal haematopoiesis and risk of chronic liver disease.Waihay J Wong, Connor Emdin, Alexander G Bick, Seyedeh M Zekavat, Abhishek Niroula
Nature. 2023-04-01 - 12 citationsAspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial.Tracey G Simon, Robert M Wilechansky, Stefania Stoyanova, Alessandra Grossman, Laura E Dichtel
JAMA. 2024-03-19 - 176 citationsSex differences in body composition and association with cardiometabolic riskMelanie Schorr, Laura E. Dichtel, Anu V. Gerweck, Ruben Valera, Martin Torriani
Biology of Sex Differences. 2018-06-27
Press Mentions
Top in Endocrinology: Nonalcoholic Fatty Liver Disease in Patients with Obesity, DiabetesJune 29th, 2022- Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call TranscriptMay 11th, 2022
- Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated TrialMay 5th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
